Cerebrospinal fluid pheresis in Guillain Barré syndrome.
While plasmapheresis is established in the treatment of acute polyneuroradiculitis, disabling pareses may last long, persisting neurological deficits remain frequent, and costs and side-effects are considerable. Repeated filtration of cerebrospinal fluid may remove pathogenetically relevant cells and polypeptides. Observations in 12 severe Guillain-Barré patients treated with CSF pheresis indicate that it is a safe and effective procedure. We hypothesize mechanisms of action of and potential indications for CSF pheresis as a more general concept. In inflammatory demyelinating polyneuropathy, CSF filtration could be combined with 'dynamic' cerebrospinal fluid pheresis, intravenous immunoglobulin therapy, cryoprecipitation, and/or immuno-adsorption to increase its effectiveness.
Wollinsky
K H
KH
Department of Anesthesiology and Intensive Care Medicine, RKU University Academic Hospital, Ulm, Germany.
Hülser
P J
PJ
Westarp
M E
ME
Mehrkens
H H
HH
Kornhuber
H H
HH
D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000134:cerebrospinal fluid / Q000628:therapy; D000936:Antigen-Antibody Complex / Q000032:analysis; D002452:Cell Count; D002469:Cell Separation / Q000379:methods*; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D005374:Filtration / Q000379:methods; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000628:therapy; D010257:Paraneoplastic Syndromes / Q000134:cerebrospinal fluid / Q000628:therapy; D011129:Polyradiculoneuropathy / Q000134:cerebrospinal fluid / Q000628:therapy*
D000936:Antigen-Antibody Complex; D002556:Cerebrospinal Fluid Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G